Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ADMA
HoldUnloved QualityADMA Biologics, Inc. · Healthcare · United States · $2.1B · Avg Vol: $20M/d
COMPANY DESCRIPTION
ADMA Biologics, Inc. is a biopharmaceutical company specializing in the development, manufacturing, and commercialization of plasma-derived therapeutics for immunocompromised patients. The company operates a vertically integrated business model, from plasma collection centers to manufacturing facilities, providing a secure supply chain and quality control for its essential products. This integration and focus on niche patient populations contribute to its competitive moat.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 154.1M | 258.2M | 426.5M | 510.2M | 49.0% | 512.3M | 535.3M | 700.3M | 17.2% |
| EPS | -0.51 | -0.33 | -0.13 | 0.85 | 0.62 | -27.1% | 0.70 | 0.75 | 0.93 | 22.3% |
| Shares | — | 221.8M | 226.1M | 236.6M | 237.9M | +7.2% | 224.0M | — | — | — |
| Debt | — | 154.4M | 141.4M | 82.1M | 79.9M | -19.7% | — | — | — | — |
| Equity | — | 152.0M | 135.2M | 349.0M | 477.3M | 46.4% | — | — | — | — |
| Op CF | — | -59.5M | 8.8M | 118.7M | 50.4M | 139.3% | 136.7M | — | — | — |
| Inv CF | — | -13.9M | -5.0M | -8.6M | -21.9M | — | — | — | — | — |
| Fin CF | — | 108.9M | -39.0M | -58.3M | -44.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ADMA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ADMA | ADMA Biologics, Inc.(you) | $2.1B | 53 | Hold |
| URGN | UroGen Pharma Ltd. | $2.1B | 51 | Hold |
| VCEL | Vericel Corporation | $2.1B | 56 | Hold |
| SEPN | Septerna, Inc. | $1.8B | 52 | Hold |
| SRPT | Sarepta Therapeutics, Inc. | $2.2B | 46 | Hold |
| FTRE | Fortrea Holdings Inc. | $1.8B | 60 | Hold |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.0B | 50 | Hold |
| OMER | Omeros Corporation | $1.3B | 48 | Hold |
| SLS | SELLAS Life Sciences Group, Inc. | $2.7B | 44 | Hold |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.1B | 44 | Hold |
Peer medians: ROE -30.8% · P/E 27.1x · Gross margin 58.1%